ACAD Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -49.65%. ACADIA Pharmaceuticals's return on equity of 41.59% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 42%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that ACADIA Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe ACADIA Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.426, which suggesting that the stock is 57.361% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ACADIA Pharmaceuticals's net income of $143.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 12.87x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.04x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of 2.31%. ACADIA Pharmaceuticals's return on equity of 41.59% beat Pfizer's return on equity of 8.91%.

ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 42%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that ACADIA Pharmaceuticals has higher upside potential than Pfizer, analysts believe ACADIA Pharmaceuticals is more attractive than Pfizer.

ACADIA Pharmaceuticals has a beta of 0.426, which suggesting that the stock is 57.361% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are smaller than Pfizer quarterly revenues of $17.8B. ACADIA Pharmaceuticals's net income of $143.7M is lower than Pfizer's net income of $410M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 12.87x while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.04x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -125.59%. ACADIA Pharmaceuticals's return on equity of 41.59% beat SpringWorks Therapeutics's return on equity of -46.69%.

ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 42%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 42.5%. Given that SpringWorks Therapeutics has higher upside potential than ACADIA Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.426, which suggesting that the stock is 57.361% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.323%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than SpringWorks Therapeutics quarterly revenues of $61.5M. ACADIA Pharmaceuticals's net income of $143.7M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 12.87x while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.04x versus 19.79x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -82.56%. ACADIA Pharmaceuticals's return on equity of 41.59% beat Verastem's return on equity of -120.71%.

ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 42%. On the other hand Verastem has an analysts' consensus of $12.57 which suggests that it could grow by 80.62%. Given that Verastem has higher upside potential than ACADIA Pharmaceuticals, analysts believe Verastem is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.426, which suggesting that the stock is 57.361% less volatile than S&P 500. In comparison Verastem has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.46%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Verastem quarterly revenues of $10M. ACADIA Pharmaceuticals's net income of $143.7M is higher than Verastem's net income of -$24M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 12.87x while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.04x versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.